Latest On Lineage Cell Therapeutics, Inc (LCTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 11:15 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 21:39 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, revenue of $2.39M beats by $0.38M | N/A | |
| 2023-03-10 10:10 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 18:48 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.15 in-line, revenue of $14.7M misses by $0.63M | N/A | |
| 2023-03-09 03:24 EST | News | Lineage Cell Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-02-22 14:45 EST | News | Lineage, Eterna team up to develop cell lines for neurological conditions | N/A | |
| 2023-01-11 11:46 EST | News | Lineage Cell Therapeutics' Cellular Treatment For Dry Age-Related Macular Degeneration | N/A | |
| 2022-11-11 12:36 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 19:10 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $3M | N/A | |
| 2022-11-10 02:15 EST | News | Lineage Cell Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-10-10 14:06 EST | News | Lineage receives U.S. patent for spinal cord injury treatment | N/A | |
| 2022-08-12 04:34 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $4.6M | N/A | |
| 2022-08-12 04:34 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-10 19:25 EST | News | Lineage Cell Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-07-20 08:45 EST | News | A Quick Look At Lineage Cell Therapeutics And Its Product Development Efforts | N/A | |
| 2022-06-02 10:57 EST | News | Lineage expands collaboration with Advanced Biomatrix for drug delivery technology | N/A | |
| 2022-05-18 09:16 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-13 19:08 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2022 Results - Earning Calls Transcript | N/A | |
| 2022-05-12 19:35 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.04 misses by $0.02, revenue of $5.24M misses by $3.66M | N/A | |
| 2022-05-12 01:23 EST | News | Lineage Cell Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-05-03 16:59 EST | News | Lineage Cell buoyed by phase 1/2a results for macular degeneration therapy | N/A | |
| 2022-04-25 23:23 EST | News | Lineage stock rises after announcing cell therapy program to treat vision loss | N/A | |
| 2022-03-24 15:52 EST | News | Lineage Cell Therapeutics CEO Brian Culley - Commercializing Cell Therapies | N/A | |
| 2022-03-11 13:57 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-10 18:13 EST | News | Lineage Cell Therapeutics GAAP EPS of -$0.17 misses by $0.12, revenue of $1.2M beats by $0.56M | N/A | |
| 2021-12-20 10:06 EST | News | Lineage jumps 11% on collaboration with Genentech in ocular disorders | N/A | |
| 2021-11-12 04:14 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2021 Earnings Conference Call - Earnings Call Transcript | N/A | |
| 2021-11-11 08:33 EST | News | Lineage Cell Therapeutics EPS in-line, beats on revenue | N/A | |
| 2021-11-11 08:33 EST | News | Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 11:00 EST | News | Lineage Cell Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-04 07:38 EST | News | Lining Up Lineage Cell Therapeutics | N/A | |
| 2021-10-01 16:44 EST | News | Lineage Cell Therapeutics (LCTX) Investor Presentation - Slideshow | N/A | |
| 2021-09-30 17:43 EST | News | Lineage Cell OpRegen interim data indicates improvement trend in visual acuity for AMD | N/A | |
| 2021-09-21 22:56 EST | News | Lineage Cell Therapeutics posts updated interim results from early-stage OpRegen study | N/A | |
| 2021-08-16 20:29 EST | News | Lineage Cell Therapeutics, Inc.s' (LCTX) CEO Brian Culley on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-13 16:11 EST | News | Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 14:13 EST | News | Lineage Cell's OpRegen results in retinal tissue restoration in dry AMD patients; shares rise 10% | N/A | |
| 2021-07-21 14:11 EST | News | Lineage Cell to join Russell 3000 and Microcap index | N/A | |
| 2021-07-21 14:10 EST | News | Updated OpRegen Data Looks Promising For Lineage | N/A | |
| 2021-07-21 14:09 EST | News | New finance chief at Lineage Cell Therapeutics | N/A | |
| 2021-07-21 14:08 EST | News | Lineage inks supply deal for HyStem biomaterial in solid tumors | N/A | |
| 2021-07-21 14:03 EST | News | Lineage’s OPC1 cell therapy for spinal cord injury to return to clinical testing | N/A | |
| 2021-07-21 13:39 EST | News | Interim early stage results show improvement in dry AMD with Lineage Cell's OpGen | N/A | |
| 2021-04-21 02:13 EST | News | Lineage shares rise after signing license and development agreement with Immunomic | N/A | |
| 2021-03-31 23:43 EST | News | CLF, CHWY, OCGN and LCTX among premarket gainers | N/A | |
| 2021-03-12 08:01 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-12 06:22 EST | News | Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue | N/A | |
| 2021-03-12 06:21 EST | News | Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-12 04:04 EST | Earnings Estimate | An EPS average of -$0.21 is estimated for the 2022 year. | Sell | |
| 2021-03-12 04:04 EST | Earnings Estimate | An EPS average of -$0.04 is estimated for the quarter ending on June 30, 2021. | Sell | |
About Lineage Cell Therapeutics, Inc (LCTX):
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
General
- Name Lineage Cell Therapeutics, Inc
- Symbol LCTX
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 49
- Last Split Factor3:1
- Last Split Date1997-10-31
- Fiscal Year EndDecember
- IPO Date1992-03-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.lineagecell.com
View More
Valuation
- Trailing PE 3.63
- Price/Sales (Trailing 12 Mt.) 127.09
- Price/Book (Most Recent Quarter) 3.78
- Enterprise Value Revenue 114.22
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.16
- Next Year EPS Estimate -$0.21
- Next Quarter EPS Estimate -$0.04
- Operating Margin -1410%
- Return on Assets -14%
- Return on Equity -20%
- Revenue 1.83 million
- Earnings Per Share $0.23
- Revenue Per Share $0.01
- Gross Profit 1.44 million
- Quarterly Earnings Growth -71.4%
View More
Highlights
- Market Capitalization 412.18 million
- EBITDA -36699000
- PE Ratio -6.9
- Analyst Target Price $5.2
- Book Value Per Share $0.78
View More
Share Statistics
- Shares Outstanding 161.64 million
- Shares Float 120.46 million
- % Held by Insiders 505%
- % Held by Institutions 35.77%
- Shares Short 3.85 million
- Shares Short Prior Month 4.6 million
- Short Ratio 2.01
- Short % of Float 3%
- Short % of Shares Outstanding 3%
View More
Technicals
- Beta 1.93
- 52 Week High $3.13
- 52 Week Low $0.65
- 50 Day Moving Average 2.48
- 200 Day Moving Average 1.7
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Lineage Cell Therapeutics, Inc (LCTX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Lineage Cell Therapeutics, Inc (LCTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | $0.01 | -$0.04 | 123.53% |
| 2020-09-30 | 2020-11-04 | $571000 | -$0.05 | -$0.05 | -11.11% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.04 | -$0.04 | 7.62% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.06 | -$0.03 | -100% |
| 2019-12-31 | 2020-03-12 | $1.24 million | -$0.03 | -$0.06 | 47.09% |
| 2019-09-30 | 2019-11-12 | $567000 | -$0.11 | -$0.05 | -106.38% |
| 2019-06-30 | 2019-08-08 | $779000 | -$0.20 | -$0.06 | -247.83% |
| 2019-03-31 | 2019-05-09 | $928000 | $0.30 | -$0.07 | 561.54% |
| 2018-12-31 | 2019-03-14 | $758000 | -$0.35 | -$0.07 | -400% |
| 2018-09-30 | 2018-11-08 | $982000 | $0.53 | -$0.07 | 857.14% |
| 2018-06-30 | 2018-08-02 | -$0.03 | -$0.09 | 65.4% | |
| 2018-03-31 | 2018-05-10 | -$0.50 | -$0.07 | -589.66% | |
| 2017-12-31 | 2018-03-15 | -$0.58 | -$0.07 | -700% | |
| 2017-09-30 | 2017-11-09 | $0.12 | -$0.08 | 244.06% | |
| 2017-06-30 | 2017-08-02 | -$0.11 | -$0.08 | -37.5% | |
| 2017-03-31 | 2017-05-10 | $0.46 | $0.36 | 27.78% | |
| 2016-12-31 | 2017-03-16 | -$0.05 | -$0.15 | 65.92% | |
| 2016-09-30 | 2016-11-03 | $1.5 million | $0.30 | -$0.14 | 309.35% |
| 2016-06-30 | 2016-08-09 | $1.27 million | $0.26 | -$0.17 | 252.94% |
| 2016-03-31 | 2016-05-10 | $2.07 million | -$0.19 | -$0.15 | -31.03% |
| 2015-12-31 | 2016-03-15 | -$0.16 | -$0.16 | 0% | |
| 2015-09-30 | 2015-11-09 | $2.31 million | -$0.18 | ||
| 2015-06-30 | 2015-08-10 | $2.01 million | -$0.12 | ||
| 2015-03-31 | 2015-05-08 | $1.26 million | -$0.13 | ||
| 2014-12-31 | 2015-03-11 | -$0.14 | |||
| 2014-09-30 | 2014-11-07 | $1.19 million | -$0.12 | ||
| 2014-06-30 | 2014-08-12 | $1.11 million | -$0.16 | ||
| 2014-03-31 | 2014-05-12 | $1.07 million | -$0.14 | ||
| 2013-12-31 | 2014-03-17 | -$0.35 | |||
| 2013-09-30 | 2013-11-13 | -$0.16 | |||
| 2013-06-30 | 2013-08-12 | -$0.14 | |||
| 2013-03-31 | 2013-05-13 | -$0.15 | |||
| 2012-12-31 | 2013-03-19 | -$0.12 | |||
| 2012-09-30 | 2012-11-12 | -$0.10 | |||
| 2012-06-30 | 2012-08-10 | -$0.11 | |||
| 2012-03-31 | 2012-05-09 | -$0.10 | |||
| 2011-12-31 | 2012-03-15 | -$0.11 | |||
| 2011-09-30 | 2011-11-09 | -$0.08 | |||
| 2011-06-30 | 2011-08-10 | -$0.09 | |||
| 2011-03-31 | 2011-05-05 | -$0.07 | |||
| 2010-12-31 | 2011-03-09 | -$0.06 | |||
| 2010-09-30 | 2010-11-15 | -$0.11 | |||
| 2010-06-30 | 2010-08-17 | -$0.06 | |||
| 2010-03-31 | 2010-05-05 | -$0.04 | |||
| 2009-12-31 | 2010-03-10 | $0.06 | |||
| 2009-09-30 | 2009-11-24 | -$0.11 | |||
| 2009-06-30 | 2009-08-14 | -$0.05 | |||
| 2009-03-31 | 2009-05-19 | -$0.06 | |||
| 2008-12-31 | 2009-03-30 | -$0.07 | |||
| 2008-09-30 | 2008-11-21 | -$0.05 | |||
| 2008-06-30 | 2008-08-15 | -$0.03 | |||
| 2008-03-31 | 2008-05-20 | -$0.02 | |||
| 2007-09-30 | 2007-11-15 | -$0.01 | |||
| 2007-06-30 | 2007-08-16 | -$0.02 | |||
| 2007-03-31 | 2007-05-16 | -$0.02 | |||
| 2006-09-30 | 2006-11-15 | -$0.02 | |||
| 2006-06-30 | 2006-08-16 | -$0.03 | -$0.02 | -50% | |
| 2006-03-31 | 2006-05-16 | -$0.02 | |||
| 2005-09-30 | 2005-11-15 | -$0.02 | -$0.04 | 50% | |
| 2005-06-30 | 2005-08-15 | -$0.02 | -$0.04 | 50% | |
| 2005-03-31 | 2005-05-17 | -$0.04 | |||
| 2004-09-30 | 2004-11-16 | -$0.03 | |||
| 2004-06-30 | 2004-08-13 | -$0.02 | |||
| 2004-03-31 | 2004-05-17 | -$0.10 | |||
| 2003-12-31 | 2004-03-29 | -$0.04 | |||
| 2003-09-30 | 2003-11-12 | $0.03 | |||
| 2003-06-30 | 2003-08-13 | -$0.06 | |||
| 2003-03-31 | 2003-03-31 | -$0.06 | |||
| 2002-12-31 | 2002-12-31 | -$0.06 | |||
| 2002-09-30 | 2002-09-30 | -$0.05 | |||
| 2002-06-30 | 2002-06-30 | -$0.07 | |||
| 2002-03-31 | 2002-03-31 | -$0.06 | |||
| 2001-12-31 | 2001-12-31 | -$0.06 | |||
| 2001-09-30 | 2001-09-30 | -$0.08 | |||
| 2001-06-30 | 2001-06-30 | -$0.10 | |||
| 2001-03-31 | 2001-03-31 | -$0.08 | |||
| 2000-09-30 | 2000-09-30 | -$0.11 | |||
| 2000-06-30 | 2000-06-30 | -$0.12 | |||
| 2000-03-31 | 2000-03-31 | -$0.12 | |||
| 1999-09-30 | 1999-09-30 | -$0.21 | |||
| 1999-06-30 | 1999-06-30 | -$0.09 | |||
| 1999-03-31 | 1999-03-31 | -$0.08 | |||
| 1998-09-30 | 1998-09-30 | -$0.11 | |||
| 1998-06-30 | 1998-08-15 | -$0.08 | -$0.10 | 20% | |
| 1998-03-31 | 1998-06-24 | -$0.11 | -$0.11 | 0% | |
| 1997-12-31 | 1998-03-19 | -$0.03 | -$0.10 | 70% | |
| 1997-09-30 | 1997-10-08 | -$0.12 | $0.04 | -400% | |
| 1997-06-30 | 1997-07-08 | -$0.06 | -$0.06 | 0% | |
| 1996-12-31 | 1997-02-20 | -$0.07 | -$0.06 | -16.67% |
Lineage Cell Therapeutics, Inc (LCTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Lineage Cell Therapeutics, Inc (LCTX) Chart:
Lineage Cell Therapeutics, Inc (LCTX) News:
Below you will find a list of latest news for Lineage Cell Therapeutics, Inc (LCTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Lineage Cell Therapeutics, Inc (LCTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 0.5 | 0.1 | CALL | 0 | 5 | 1373.06 | FALSE | 0 | 0 |
| 2025-05-16 | 1 | 0 | CALL | 0 | 0 | 515.42 | FALSE | 0 | 0 |
| 2025-05-16 | 1.5 | 0.05 | CALL | 0 | 150 | 339.31 | FALSE | 0 | 0 |
| 2025-05-16 | 2 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 0.5 | 0 | PUT | 0 | 0 | 406.75 | TRUE | 0 | 0 |
| 2025-05-16 | 1 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-05-16 | 1.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-05-16 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-06-20 | 0.5 | 0.05 | CALL | 5 | 2018 | 137.6 | FALSE | -0.08 | -0.62 |
| 2025-06-20 | 1 | 0.05 | CALL | 0 | 652 | 191.22 | FALSE | 0 | 0 |
| 2025-06-20 | 1.5 | 0.1 | CALL | 0 | 276 | 236.17 | FALSE | 0 | 0 |
| 2025-06-20 | 2 | 0.05 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2025-06-20 | 2.5 | 0.1 | CALL | 0 | 1621 | 286.98 | FALSE | 0 | 0 |
| 2025-06-20 | 5 | 0 | CALL | 0 | 0 | 406.07 | FALSE | 0 | 0 |
| 2025-06-20 | 7.5 | 0.25 | CALL | 0 | 120 | 0 | FALSE | 0 | 0 |
| 2025-06-20 | 0.5 | 0 | PUT | 0 | 0 | 181.57 | TRUE | 0 | 0 |
| 2025-06-20 | 1 | 0 | PUT | 0 | 0 | 847.76 | TRUE | 0 | 0 |
| 2025-06-20 | 1.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-06-20 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-06-20 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-06-20 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-06-20 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-09-19 | 0.5 | 0.1 | CALL | 0 | 1871 | 160.58 | FALSE | 0 | 0 |
| 2025-09-19 | 1 | 0.05 | CALL | 0 | 787 | 169.83 | FALSE | 0 | 0 |
| 2025-09-19 | 1.5 | 0.05 | CALL | 0 | 50 | 230.55 | FALSE | 0 | 0 |
| 2025-09-19 | 2 | 0.05 | CALL | 0 | 11 | 307.35 | FALSE | 0 | 0 |
| 2025-09-19 | 2.5 | 0.25 | CALL | 0 | 20 | 482.15 | FALSE | 0 | 0 |
| 2025-09-19 | 5 | 0 | CALL | 0 | 0 | 275.88 | FALSE | 0 | 0 |
| 2025-09-19 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-09-19 | 0.5 | 0.05 | PUT | 0 | 10 | 149.96 | TRUE | 0 | 0 |
| 2025-09-19 | 1 | 0.66 | PUT | 0 | 20 | 554.95 | TRUE | 0 | 0 |
| 2025-09-19 | 1.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-09-19 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-09-19 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-09-19 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-09-19 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 0.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 1 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 1.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 2 | 0 | CALL | 0 | 0 | 186.63 | FALSE | 0 | 0 |
| 2025-12-19 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-12-19 | 0.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 1 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 1.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 2.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2025-12-19 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
Latest LCTX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:58 PM EST | 100 | $1.315 |
| Jun 13, 2022 7:58 PM EST | 40 | $1.315 |
| Jun 13, 2022 7:58 PM EST | 100 | $1.32 |
| Jun 13, 2022 7:59 PM EST | 80 | $1.315 |
| Jun 13, 2022 7:59 PM EST | 40 | $1.315 |
Lineage Cell Therapeutics, Inc (LCTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957420004437/0000919574-20-004437-index.htm |
| 2020-05-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/876343/000000000020003972/0000000000-20-003972-index.htm |
| 2019-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957419002297/0000919574-19-002297-index.htm |
| 2019-03-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000091957419002304/0000919574-19-002304-index.htm |
| 2019-04-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957419002988/0000919574-19-002988-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957419004450/0000919574-19-004450-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000091957420004437/0000919574-20-004437-index.htm |
| 2018-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919118054606/0001209191-18-054606-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919118063602/0001209191-18-063602-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919118063604/0001209191-18-063604-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119001577/0001209191-19-001577-index.htm |
| 2019-01-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119003171/0001209191-19-003171-index.htm |
| 2019-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119003173/0001209191-19-003173-index.htm |
| 2019-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119010466/0001209191-19-010466-index.htm |
| 2019-03-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119019553/0001209191-19-019553-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119019722/0001209191-19-019722-index.htm |
| 2019-03-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119020847/0001209191-19-020847-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119020852/0001209191-19-020852-index.htm |
| 2019-03-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119021866/0001209191-19-021866-index.htm |
| 2019-04-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119023894/0001209191-19-023894-index.htm |
| 2019-05-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119032066/0001209191-19-032066-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119032073/0001209191-19-032073-index.htm |
| 2019-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119040588/0001209191-19-040588-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041304/0001209191-19-041304-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041306/0001209191-19-041306-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041308/0001209191-19-041308-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041310/0001209191-19-041310-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041312/0001209191-19-041312-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041314/0001209191-19-041314-index.htm |
| 2019-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119041335/0001209191-19-041335-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119046029/0001209191-19-046029-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119046030/0001209191-19-046030-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000120919119046031/0001209191-19-046031-index.htm |
| 2018-11-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315218015403/0001493152-18-015403-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315218015404/0001493152-18-015404-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315218015405/0001493152-18-015405-index.htm |
| 2018-11-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315218015406/0001493152-18-015406-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315218015428/0001493152-18-015428-index.htm |
| 2018-11-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315218015487/0001493152-18-015487-index.htm |
| 2018-11-09 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315218015519/0001493152-18-015519-index.htm |
| 2018-12-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315218017003/0001493152-18-017003-index.htm |
| 2018-12-06 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315218017079/0001493152-18-017079-index.htm |
| 2018-12-06 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315218017082/0001493152-18-017082-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315218017721/0001493152-18-017721-index.htm |
| 2019-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219000147/0001493152-19-000147-index.htm |
| 2019-01-04 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315219000195/0001493152-19-000195-index.htm |
| 2019-01-14 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315219000513/0001493152-19-000513-index.htm |
| 2019-02-04 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/876343/000149315219001332/0001493152-19-001332-index.htm |
| 2019-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219001907/0001493152-19-001907-index.htm |
| 2019-02-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219002426/0001493152-19-002426-index.htm |
| 2019-03-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219002770/0001493152-19-002770-index.htm |
| 2019-03-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/876343/000149315219002772/0001493152-19-002772-index.htm |
| 2019-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219003026/0001493152-19-003026-index.htm |
| 2019-03-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315219003107/0001493152-19-003107-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/876343/000149315219003335/0001493152-19-003335-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219003346/0001493152-19-003346-index.htm |
| 2019-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219003570/0001493152-19-003570-index.htm |
| 2019-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219005752/0001493152-19-005752-index.htm |
| 2019-04-25 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219005938/0001493152-19-005938-index.htm |
| 2019-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219006051/0001493152-19-006051-index.htm |
| 2019-04-30 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/876343/000149315219006175/0001493152-19-006175-index.htm |
| 2019-05-01 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/876343/000149315219006257/0001493152-19-006257-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219006272/0001493152-19-006272-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315219006673/0001493152-19-006673-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219006686/0001493152-19-006686-index.htm |
| 2019-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219006740/0001493152-19-006740-index.htm |
| 2019-06-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/876343/000149315219009214/0001493152-19-009214-index.htm |
| 2019-06-14 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/876343/000149315219009216/0001493152-19-009216-index.htm |
| 2019-07-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219010315/0001493152-19-010315-index.htm |
| 2019-07-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315219010320/0001493152-19-010320-index.htm |
| 2019-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219011338/0001493152-19-011338-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219011902/0001493152-19-011902-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315219011906/0001493152-19-011906-index.htm |
| 2019-08-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/876343/000149315219011912/0001493152-19-011912-index.htm |
| 2019-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219012036/0001493152-19-012036-index.htm |
| 2019-09-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315219014106/0001493152-19-014106-index.htm |
| 2019-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315219014109/0001493152-19-014109-index.htm |
| 2019-09-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219014295/0001493152-19-014295-index.htm |
| 2019-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315219014321/0001493152-19-014321-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315219014834/0001493152-19-014834-index.htm |
| 2019-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219015458/0001493152-19-015458-index.htm |
| 2019-10-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219015684/0001493152-19-015684-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315219016899/0001493152-19-016899-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315219016930/0001493152-19-016930-index.htm |
| 2019-12-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315219019942/0001493152-19-019942-index.htm |
| 2020-01-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315220000239/0001493152-20-000239-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220000240/0001493152-20-000240-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220000483/0001493152-20-000483-index.htm |
| 2020-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220002547/0001493152-20-002547-index.htm |
| 2020-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315220002548/0001493152-20-002548-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220003812/0001493152-20-003812-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/876343/000149315220003818/0001493152-20-003818-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220004349/0001493152-20-004349-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220004350/0001493152-20-004350-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220004351/0001493152-20-004351-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220004352/0001493152-20-004352-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220005529/0001493152-20-005529-index.htm |
| 2020-04-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/876343/000149315220007179/0001493152-20-007179-index.htm |
| 2020-04-28 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/876343/000149315220007279/0001493152-20-007279-index.htm |
| 2020-05-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/876343/000149315220007529/0001493152-20-007529-index.htm |
| 2020-05-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/876343/000149315220007837/0001493152-20-007837-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220007954/0001493152-20-007954-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315220007956/0001493152-20-007956-index.htm |
| 2020-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220009635/0001493152-20-009635-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012529/0001493152-20-012529-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012533/0001493152-20-012533-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012536/0001493152-20-012536-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012538/0001493152-20-012538-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012539/0001493152-20-012539-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012541/0001493152-20-012541-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220012542/0001493152-20-012542-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220014854/0001493152-20-014854-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000149315220014858/0001493152-20-014858-index.htm |
| 2020-08-10 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/876343/000149315220014990/0001493152-20-014990-index.htm |
| 2020-08-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/876343/000149315220014995/0001493152-20-014995-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220017696/0001493152-20-017696-index.htm |
| 2020-09-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000149315220018240/0001493152-20-018240-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/876343/000149315220018634/0001493152-20-018634-index.htm |
| 2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/876343/000164117220000028/0001641172-20-000028-index.htm |
| 2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/876343/000164117220000034/0001641172-20-000034-index.htm |
| 2020-05-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/876343/999999999520001104/9999999995-20-001104-index.htm |
Lineage Cell Therapeutics, Inc (LCTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lineage Cell Therapeutics, Inc (LCTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 505%Institutional Ownership: 3577%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-01-01 | Brian M Culley | President and CEO | Buy | 100,000.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119001577/0001209191-19-001577-index.htm | ||
| 2019-07-05 | BIOTIME INC | 10% Share Holder | Sell | 2,250,000.00 | 2.00 | 4,500,000.00 | 12,424,244.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119041335/0001209191-19-041335-index.htm |
| 2018-10-04 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | 11,250.00 | 13,250.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919118054606/0001209191-18-054606-index.htm | ||
| 2019-09-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 140,410.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315219014834/0001493152-19-014834-index.htm | ||
| 2019-09-17 | Brian M Culley | President and CEO | Buy | 61,800.00 | 146,331.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315219014321/0001493152-19-014321-index.htm | ||
| 2019-12-31 | Brian M Culley | President and CEO | Buy | 15,450.00 | 150,517.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315219019942/0001493152-19-019942-index.htm | ||
| 2020-03-31 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.83 | 12,794.15 | 160,624.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315220005529/0001493152-20-005529-index.htm |
| 2020-06-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.87 | 13,441.50 | 170,731.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315220012542/0001493152-20-012542-index.htm |
| 2020-09-30 | Brian M Culley | President and CEO | Buy | 15,450.00 | 0.94 | 14,470.47 | 180,838.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315220018634/0001493152-20-018634-index.htm |
| 2019-03-08 | Michael H. Mulroy | Director | Buy | 194,271.00 | 226,821.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119019722/0001209191-19-019722-index.htm | ||
| 2018-12-18 | RUSSELL SKIBSTED | Chief Financial Officer | Buy | 22,500.00 | 31,859.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919118063604/0001209191-18-063604-index.htm | ||
| 2019-08-13 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 33,990,826.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm | ||
| 2019-08-13 | BROADWOOD PARTNERS, L.P. | Director | Buy | 10,000.00 | 0.99 | 9,949.00 | 33,990,826.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm |
| 2019-08-14 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 33,992,233.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm | ||
| 2019-08-14 | BROADWOOD PARTNERS, L.P. | Director | Buy | 1,407.00 | 0.98 | 1,378.86 | 33,992,233.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm |
| 2019-08-15 | BROADWOOD PARTNERS, L.P. | Director | Buy | 0.00 | 34,005,379.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm | ||
| 2019-08-15 | BROADWOOD PARTNERS, L.P. | Director | Buy | 13,146.00 | 0.97 | 12,717.44 | 34,005,379.00 | https://www.sec.gov/Archives/edgar/data/876343/000091957419005442/0000919574-19-005442-index.htm |
| 2018-12-18 | Stephana Eilene Patton | General Counsel & Secretary | Buy | 27,500.00 | 43,995.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919118063602/0001209191-18-063602-index.htm | ||
| 2019-08-13 | Brandi Roberts | CFO & SVP, Finance | Buy | 5,000.00 | 1.01 | 5,050.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119046030/0001209191-19-046030-index.htm |
| 2019-08-13 | Chase C. Leavitt | General Counsel/Secretary | Buy | 5,000.00 | 1.02 | 5,100.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119046031/0001209191-19-046031-index.htm |
| 2019-03-08 | ALFRED D KINGSLEY | Director | Buy | 6,390.00 | 5,457,945.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119023894/0001209191-19-023894-index.htm | ||
| 2020-01-02 | Lineage Cell Therapeutics, Inc. | Insider | Sell | 2,383,090.00 | 2.16 | 5,137,942.04 | 6,041,154.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315220000240/0001493152-20-000240-index.htm |
| 2019-09-11 | Lineage Cell Therapeutics, Inc. | 10% Share Holder | Sell | 4,000,000.00 | 1.66 | 6,640,000.00 | 8,424,244.00 | https://www.sec.gov/Archives/edgar/data/876343/000149315219014109/0001493152-19-014109-index.htm |
| 2019-08-13 | Brian M Culley | President and CEO | Buy | 10,000.00 | 1.01 | 10,100.00 | 84,531.00 | https://www.sec.gov/Archives/edgar/data/876343/000120919119046029/0001209191-19-046029-index.htm |